ClinicalTrials.gg
RecruitingNCT05455489Updated Mar 4, 2024

GISE Registry of Transcatheter Treatment of Mitral Valve Regurgitation With the MitraClip G4

An observational study in Mitral Valve Regurgitation, sponsored by Fondazione GISE Onlus. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-04.

Sponsored by Fondazione GISE Onlus · Observational

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
264
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 63 studies in Mitral Valve Insufficiency with a site in Italy — 20 open to participants now, 28 under way, none of them phase 3. Mitral Valve Insufficiency · Italy.

Planned enrollment
13th of 33
264 · median 200
Started
2023
with 2 others
Observational
33 of 63
11 open now
Primary completion
2029-08
later than 21 of 27 live
Registered
43rd of 63
by date

Among the 63 studies in Mitral Valve Insufficiency with a site in Italy, this one is the 13th largest by planned enrollment of the 33 observational ones that give a count, is one of 3 that started in 2023, is one of 33 observational ones, reaches primary completion later than 21 of the 27 other live ones, and was the 43rd registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

20 of the 63 studies in Mitral Valve Insufficiency with a site in Italy are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Mitral Valve Insufficiency with a site in Italy, or all of them as a file.
02

Study summary

The aim of the GISE study is to confirm the MitraClip safety and improve the device effectiveness in a selected all comers ("more-comers") population with symptomatic severe mitral regurgitation undergoing/undergone Transcatheter Edge-to-Edge Repair (TEER) with MitraClip G4.

03

Conditions studied

  • Mitral Valve Regurgitation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients undergoing/undergone to TEER procedure with MitraClip G4 in selected hospitals linked to the GISE network. Patients should meet all the inclusion criteria and none of the exclusion criteria; such criteria will identify a selected all comers ("more-comers") population which includes the vast majority of patients treated with MitraClip in daily practice. Retrospective enrolments are allowed if available data are in line with the study requirements and the patients can give their consent to be enrolled in the study informed consent process. Patients who don't meet one or more of the inclusion criteria or met at least one exclusion criteria are excluded from the study; however, a selected list of baseline/procedural features and follow-up data will be recorded for excluded patients.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

SUBGROUP A: FUNCTIONAL MR Patients with symptomatic severe secondary MR (3-4+, according to the multiparametric study algorithm), both ischemic or non-ischemic etiology, on optimal medical therapy AND

  • Left Ventricular End-Systolic Dimension \<70 mm
  • Mitral Valve area > 4 cmq
  • ≥20%
  • functional class II, III, ambulatory IV
  • brain natriuretic peptide BNP ≥300 pg/ml or N-terminal prohormone of brain natriuretic peptide NT-proBNP ≥1500 pg/ml and/or at least one hosp for HF (Heart failure) in the 12 months prior to enrollment
  • Age 18 years or older
  • Subject has been adequately treated per applicable standards, including for coronary artery disease, LV (left ventricular) dysfunction, MR Mitral (regurgitation) and HF
  • Local Heart-team decision SUBGROUP B: DEGENERATIVE MR Patients with symptomatic severe primary MR (3-4+, according to the multiparametric study algorithm) AND
  • Mobile mitral valve (MV) length of PL ≥8 mm in case of NT device, ≥10 mm in case of XT device
  • MV area > 4 cm2
  • NYHA functional class > II
  • Age 18 years or older
  • Local HT decision In case of patients with a coexistence of both etiologies, they will be assigned to a subgroup based on the prevailing mechanism.

THE MULTIPARAMETRIC ALGORITHM FOR MR GRADING The multiparametric algorithm, adapted from the criteria recommended by the American Society of Echocardiography 2003 Guidelines and based on 3 tiers of evaluation, will be used for qualification purposes to determine if MR was 3+ or higher. The 3 tiers of evaluation are applied in a hierarchical manner (from tier 1 to 3) and patients qualified for TEER by meeting the criteria of at least one of them. For MR grading purposes, MR severity was subsequently graded as 3+ or 4+ based on the integrative evaluation of multiple parameters recommended by the The American Society of Echocardiography (ASE)

Exclusion criteria

Exclusion Criteria:

  • Significant right ventricular disfunction (TAPSE\<15 mm and/or S'\<8cm/s)
  • Systolic pulmonary artery > 70 mmHg with irreversible precapillary pulmonary hypertension
  • Severe TR Tricuspid valve regurgitation
  • Hemodynamic instability/ IV
  • Impaired mobility as a result of neurological or musculoskeletal disease, or advanced dementia
  • Leaflet anatomy which may preclude MitraClip implantation, proper MitraClip positioning on the leaflets or sufficient reduction in MR by the MitraClip
  • Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, infiltrative cardiomyopathies
  • CABG coronary artery bypass graft, PCI percutaneous coronary intervention, TAVR transcatheter aortic valve replacement, CVA cardiovascular accident within the prior 60 days
  • \<12 months due to non-cardiac conditions
  • Active infections
  • Advanced HF (ESC/HFA Heart Failure Association Criteria) or Bridge tp to HTx/LVAD (left ventricular assist device)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
264 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • FUNCTIONAL MR

    Patients with symptomatic severe secondary MR (3-4+, according to the multiparametric study algorithm), both ischemic or non-ischemic etiology, on optimal medical therapy

  • DEGENERATIVE MR

    Patients with symptomatic severe primary MR (3-4+, according to the multiparametric study algorithm)

06

What researchers measure

Primary outcomes

  1. percentage of participants with a mitral regurgitation (MR)

    grade ≤1+. Two separates subgroups will be identified according to the presence of functional (FMR) or degenerative (DMR) mitral valve disease.

    Time frame: at 30 days

  2. percentage of participants with a mitral regurgitation (MR)

    grade ≤1+. Two separates subgroups will be identified according to the presence of functional (FMR) or degenerative (DMR) mitral valve disease.

    Time frame: at 1 year

Secondary outcomes

  1. composite of all-cause death and hospitalization for heart failure (HF),

    all-cause death, cardiovascular death and non-cardiovascular death, myocardial infarction, hospitalizations for HF,

    Time frame: at 30 days

  2. composite of all-cause death and hospitalization for heart failure (HF),

    all-cause death, cardiovascular death and non-cardiovascular death, myocardial infarction, hospitalizations for HF,

    Time frame: at 1 year

  3. composite of all-cause death and hospitalization for heart failure (HF),

    all-cause death, cardiovascular death and non-cardiovascular death, myocardial infarction, hospitalizations for HF,

    Time frame: at 2 years

  4. composite of all-cause death and hospitalization for heart failure (HF),

    all-cause death, cardiovascular death and non-cardiovascular death, myocardial infarction, hospitalizations for HF,

    Time frame: at 3 years

  5. composite of all-cause death and hospitalization for heart failure (HF),

    all-cause death, cardiovascular death and non-cardiovascular death, myocardial infarction, hospitalizations for HF,

    Time frame: at 4 years

  6. composite of all-cause death and hospitalization for heart failure (HF),

    all-cause death, cardiovascular death and non-cardiovascular death, myocardial infarction, hospitalizations for HF,

    Time frame: at 5 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Aug 2029, 78 months after the start.

Of 73 non-industry observational studies under Mitral Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 192. This study's planned 78 months is above that.

Counting every sponsor, half of 85 studies reached it within 57 months; a quarter within 26 and three quarters within 192.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2022
First posted
Jul 13, 2022
StartActual
Jan 25, 2023
Primary completionEst.
Aug 1, 2029
CompletionEst.
Aug 1, 2029
Last update
Mar 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05455489
Lead sponsor
Fondazione GISE Onlus
Responsible party
Sponsor
First posted
Jul 13, 2022
Start date
Jan 25, 2023
Primary completion
Aug 1, 2029 (estimated)
Completion
Aug 1, 2029 (estimated)
Last update
Mar 4, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion